Abstract
We aimed to develop a more efficient prognostic model to predict 1-year mortality in patients with hepatitis B virus-related decompensated cirrhosis beginning antiviral treatment. Using Cox regression analysis, survival analyses were performed on 554 patients with decompensated cirrhosis who were followed up from the start of nucleos(t)ide analogue antiviral treatment. At baseline, ascites and hepatic encephalopathy were found in 78.0% and 18.1% of patients, respectively. Eighty-six events (77 deaths and 9 emergency liver transplants) occurred within the first year of treatment. Severity of ascites, presence of hepatic encephalopathy, and the Model for End-Stage Liver Disease (MELD)-sodium (MELDNa) score were independent risk factors for 1-year mortality. The new prognostic model (the revised MELDNa) constructed by adding ascites and encephalopathy to the MELDNa score significantly improved the area under the receiver operating characteristics curve for predicting 1-year events at baseline compared with the Child-Turcotte-Pugh system, MELD and MELDNa models, and Fontana index (0.905 vs 0.867, 0.843, 0.871, and 0.815, respectively; P < 0.05). Furthermore, repetitive application of revised MELDNa at 0, 1, 2, 3, and 6 months of tr...Continue Reading
References
Aug 1, 1973·The British Journal of Surgery·R N PughR Williams
Jan 1, 1996·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·V ArroyoJ Schölmerich
Apr 9, 1999·Vaccine·E E MastH S Margolis
Apr 30, 1999·BMJ : British Medical Journal·A J Zuckerman
Dec 29, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J P VilleneuveE J Heathcote
Mar 25, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M MalinchocP C ter Borg
Feb 15, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R P PerrilloUNKNOWN Lamivudine North American Transplant Group
Aug 29, 2002·Gastroenterology·Robert J FontanaNathaniel A Brown
Mar 5, 2003·Seminars in Liver Disease·Giovanna Fattovich
Oct 8, 2004·The New England Journal of Medicine·Yun-Fan LiawUNKNOWN Cirrhosis Asian Lamivudine Multicentre Study Group
Feb 28, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Patrick S KamathUNKNOWN Advanced Liver Disease Study Group
Dec 22, 2007·Journal of Hepatology·Giovanna FattovichFrancesco Donato
Sep 5, 2008·The New England Journal of Medicine·W Ray KimTerry M Therneau
Dec 17, 2009·Journal of Hepatology·Ju Hyun ShimDong Jin Suh
Dec 17, 2009·Journal of Hepatology·Robert J Fontana
Dec 25, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert S O'SheaUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Apr 7, 2010·The Korean Journal of Hepatology·Hee Bok ChaeHyung Joon Yim
Apr 7, 2010·The Korean Journal of Hepatology·Jeong Won Jang
Dec 15, 2010·Journal of Hepatology·Juan Córdoba
Nov 22, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·Jong Jin HyunHo Sang Ryu
Jan 20, 2012·Alimentary Pharmacology & Therapeutics·A K Singal, R J Fontana
Jan 26, 2012·Vaccine·J J OttS T Wiersma
May 5, 2012·Journal of Gastroenterology and Hepatology·Chang Ha KimHo Sang Ryu
Jan 30, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jeong Won JangKwang-Hyub Han
Nov 14, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F LokKhaled Mohammed